{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:49:01Z","timestamp":1766173741149,"version":"3.48.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":324,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.101044","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:06:32Z","timestamp":1763827592000},"page":"101044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5742-829X","authenticated-orcid":false,"given":"H. Lawrence","family":"Remmel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7760-4582","authenticated-orcid":false,"given":"Sandra S.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-470X","authenticated-orcid":false,"given":"John R.","family":"Hawse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-2551","authenticated-orcid":false,"given":"Anastasia","family":"Shneyderman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1006-5944","authenticated-orcid":false,"given":"Alexander","family":"Veviorskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9208-9131","authenticated-orcid":false,"given":"Khadija M.","family":"Alawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1866-4318","authenticated-orcid":false,"given":"Mikhail","family":"Korzinkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8966","authenticated-orcid":false,"given":"Alex","family":"Zhavoronkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-7651","authenticated-orcid":false,"given":"Steven C.","family":"Quay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.101044_bib0001","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/ijms22020756","article-title":"A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses","volume":"22","author":"Clusan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2025.101044_bib0002","first-page":"405","article-title":"Endocrine therapy for early breast cancer: updated review","volume":"17","author":"Tremont","year":"2017","journal-title":"Ochsner J."},{"key":"10.1016\/j.ctarc.2025.101044_bib0003","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctarc.2025.101044_bib0004","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1001\/jama.1979.03290490018014","article-title":"Tamoxifen flare","volume":"241","author":"Veldhuis","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2025.101044_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092535","article-title":"Tamoxifen and endometrial cancer: a Janus-headed drug","volume":"12","author":"Emons","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2025.101044_bib0006","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1186\/s12885-021-08268-8","article-title":"Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review","volume":"21","author":"Chan","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0007","first-page":"3402","article-title":"CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver","volume":"57","author":"Dehal","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0750305","article-title":"A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity","volume":"75","author":"Jordan","year":"1977","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","article-title":"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen","volume":"85","author":"Johnson","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2025.101044_bib0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/jpet.104.065607","article-title":"Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6","volume":"310","author":"Desta","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ctarc.2025.101044_bib0011","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-004-0926-7","article-title":"Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen","volume":"55","author":"Lim","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Jin","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2025.101044_bib0013","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/clpt.2011.27","article-title":"Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma","volume":"89","author":"M\u00fcrdter","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2025.101044_bib0014","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1373\/clinchem.2008.121756","article-title":"Pharmacogenomics of tamoxifen therapy","volume":"55","author":"Brauch","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ctarc.2025.101044_bib0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/cts.12707","article-title":"The influences of adherence to tamoxifen and CYP2D6 pharmacogenetics on plasma concentrations of the active metabolite (Z)-endoxifen in breast cancer","volume":"13","author":"Nardin","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ctarc.2025.101044_bib0016","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2025.101044_bib0017","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/tpj.2014.34","article-title":"Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer","volume":"15","author":"Saladores","year":"2015","journal-title":"Pharmacogen. J."},{"key":"10.1016\/j.ctarc.2025.101044_bib0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13058-017-0916-4","article-title":"Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients","volume":"19","author":"Helland","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0019","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.clpt.6100367","article-title":"Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response","volume":"83","author":"Goetz","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2025.101044_bib0020","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2009.1420","article-title":"Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen","volume":"302","author":"Schroth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2025.101044_bib0021","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-08-3933","article-title":"The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054613","article-title":"Endoxifen\u2019s molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens","volume":"8","author":"Hawse","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2025.101044_bib0023","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13058-020-01286-7","article-title":"Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer","volume":"22","author":"Jayaraman","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0024","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41523-023-00606-2","article-title":"Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in er\u03b1+ breast cancer","volume":"9","author":"Jayaraman","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0025","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.2017.73.3246","article-title":"First-in-Human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0026","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab191","article-title":"Endoxifen, an estrogen receptor targeted therapy: from bench to bedside","volume":"162","author":"Jayaraman","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctarc.2025.101044_bib0027","doi-asserted-by":"crossref","first-page":"268","DOI":"10.18632\/oncotarget.27887","article-title":"Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors","volume":"12","author":"Takebe","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2025.101044_bib0028","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/1541-7786.MCR-20-0872","article-title":"Development and characterization of novel endoxifen-resistant breast cancer cell lines highlight numerous differences from tamoxifen-resistant models","volume":"19","author":"Jones","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0029","article-title":"Comparative analysis of endoxifen, tamoxifen and fulvestrant: a bioinformatics approach to uncover mechanisms of action in breast cancer","author":"Remmel","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ctarc.2025.101044_bib0030","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1021\/acs.jcim.3c01619","article-title":"PandaOmics: an AI-driven platform for therapeutic target and biomarker discovery","volume":"64","author":"Kamya","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ctarc.2025.101044_bib0031","doi-asserted-by":"crossref","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets\u2013update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0032","doi-asserted-by":"crossref","first-page":"D747","DOI":"10.1093\/nar\/gkl995","article-title":"ArrayExpress\u2013a public database of microarray experiments and gene expression profiles","volume":"35","author":"Parkinson","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0033","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1055-9965.EPI-19-0066","article-title":"MCF-7 as a model for functional analysis of breast cancer risk variants","volume":"28","author":"Booms","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ctarc.2025.101044_bib0034","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Series B Stat. Methodol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0036","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btac757","article-title":"GSEApy: a comprehensive package for performing gene set enrichment analysis in Python","volume":"39","author":"Fang","year":"2023","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ctarc.2025.101044_bib0037","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13104-016-2331-9","article-title":"Differential correlation for sequencing data","volume":"10","author":"Siska","year":"2017","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ctarc.2025.101044_bib0038","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/oncolo\/oyad049","article-title":"Revisiting androgen receptor signaling in breast cancer","volume":"28","author":"Dai","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2025.101044_bib0039","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/cancers14215206","article-title":"Molecular mechanisms of anti-estrogen therapy resistance and novel targeted therapies","volume":"14","author":"Ozyurt","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2025.101044_bib0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1448687","article-title":"Mechanisms of endocrine resistance in hormone receptor-positive breast cancer","volume":"14","author":"Gao","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0042","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014A mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0043","article-title":"ESR1 fusions and therapeutic resistance in metastatic breast cancer","volume":"12","author":"Nagy","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0044","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-018-5023-4","article-title":"Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals","volume":"173","author":"Szostakowska","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2025.101044_bib0045","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","article-title":"Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies","volume":"99","author":"Saatci","year":"2021","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ctarc.2025.101044_bib0046","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/0008-5472.CAN-23-0184","article-title":"Metabolomic rewiring promotes endocrine therapy resistance in breast cancer","volume":"84","author":"Ahn","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0047","article-title":"An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2025.101044_bib0048","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ddmec.2012.10.003","article-title":"Antiestrogen resistance and the application of systems biology","volume":"9","author":"Bouker","year":"2012","journal-title":"Drug Discov. Today Dis. Mech."},{"key":"10.1016\/j.ctarc.2025.101044_bib0049","doi-asserted-by":"crossref","first-page":"600","DOI":"10.18632\/oncotarget.28225","article-title":"A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis","volume":"13","author":"Asghari","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2025.101044_bib0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00428-021-03213-3","article-title":"Artificial intelligence applied to breast pathology","volume":"480","author":"Yousif","year":"2022","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ctarc.2025.101044_bib0051","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ctarc.2025.101044_bib0052","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors: a quantum leap in the treatment of advanced breast cancers","volume":"14","author":"Reddy","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ctarc.2025.101044_bib0053","unstructured":"ClinicalTrials.Gov. https:\/\/clinicaltrials.gov\/study\/NCT01042379?term=NCT01042379&rank=1."},{"key":"10.1016\/j.ctarc.2025.101044_bib0054","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/DDDT.S336643","article-title":"The role of progesterone receptors in breast cancer","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ctarc.2025.101044_bib0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","article-title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges","volume":"126","author":"Herzog","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0056","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.21873\/invivo.12618","article-title":"Kallikrein 11 down-regulation in breast carcinoma: correlation with prognostic parameters","volume":"35","author":"Ozturk","year":"2021","journal-title":"In Vivo (Brooklyn)"},{"key":"10.1016\/j.ctarc.2025.101044_bib0057","first-page":"3902","article-title":"Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells","volume":"55","author":"Teixeira","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0058","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-8-153","article-title":"Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer","volume":"8","author":"Callagy","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020279","article-title":"Regulation of bcl-2 Family proteins in estrogen receptor-positive breast cancer and their implications in endocrine therapy","volume":"14","author":"Kawiak","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2025.101044_bib0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-319-91439-8_11","article-title":"Venetoclax: targeting BCL2 in hematological cancers","volume":"212","author":"Scheffold","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0061","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","article-title":"VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors - efficacy, safety, and biomarker results","volume":"28","author":"Lindeman","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0062","doi-asserted-by":"crossref","first-page":"355","DOI":"10.37349\/etat.2020.00021","article-title":"Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in er\u03b1-positive breast cancer","volume":"1","author":"Volpato","year":"2020","journal-title":"Explor. Target. Antitumor Ther."},{"key":"10.1016\/j.ctarc.2025.101044_bib0063","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.21873\/anticanres.17785","article-title":"High expression of pkc\u03b6 and ALDH1A3 is associated with poor prognosis in luminal B breast cancer","volume":"45","author":"Nagashima","year":"2025","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0064","first-page":"466","article-title":"Differences in androgen receptor expression in human heart tissue in various types of cardiomyopathy and in aortic valve stenosis","volume":"10","author":"Eildermann","year":"2023","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.ctarc.2025.101044_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79177-2","article-title":"The androgen receptor expression and its activity have different relationships with prognosis in hepatocellular carcinoma","volume":"10","author":"Acosta-Lopez","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2025.101044_bib0066","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10147-008-0770-6","article-title":"Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers","volume":"13","author":"Ogawa","year":"2008","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0067","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1078-0432.CCR-10-2021","article-title":"Androgen receptor expression and breast cancer survival in postmenopausal women","volume":"17","author":"Hu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0068","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.humpath.2011.08.007","article-title":"Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy","volume":"43","author":"Cimino-Mathews","year":"2012","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0069","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41523-019-0142-6","article-title":"Androgen receptor gene expression in primary breast cancer","volume":"5","author":"Vidula","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0070","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/PAI.0000000000000234","article-title":"Expression of androgen receptor in estrogen receptor-positive breast cancer","volume":"24","author":"Agrawal","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0071","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13058-019-1118-z","article-title":"Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98","volume":"21","author":"Kensler","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-009-0436-8","article-title":"Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells","volume":"121","author":"De Amicis","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2025.101044_bib0073","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00280-019-03891-6","article-title":"A high AR:er\u03b1 or PDEF:er\u03b1 ratio predicts a sub-optimal response to tamoxifen therapy in er\u03b1-positive breast cancer","volume":"84","author":"Cao","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0074","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr3599","article-title":"Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide","volume":"16","author":"Cochrane","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315342","article-title":"Modulating the activity of androgen receptor for treating breast cancer","volume":"23","author":"You","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2025.101044_bib0076","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-020-00649-z","article-title":"Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer","volume":"18","author":"Bahnassy","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ctarc.2025.101044_bib0077","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1158\/1078-0432.CCR-20-1693","article-title":"A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer","volume":"26","author":"Krop","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0078","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3426407","article-title":"Managing cancer drug resistance from the perspective of inflammation","volume":"2022","author":"Lu","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0079","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-12-1000","article-title":"Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance","volume":"19","author":"Dunbier","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205130","article-title":"Enhanced IFN\u03b1 signaling promotes Ligand-independent activation of ER\u03b1 to promote aromatase inhibitor resistance in breast cancer","volume":"13","author":"Escher","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2025.101044_bib0081","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13058-014-0506-7","article-title":"Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death","volume":"17","author":"Choi","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0082","doi-asserted-by":"crossref","first-page":"58338","DOI":"10.18632\/oncotarget.16873","article-title":"Inflammatory factor TNF-\u03b1 promotes the growth of breast cancer via the positive feedback loop of TNFR1\/NF-\u03bab (and\/or p38)\/p-STAT3\/HBXIP\/TNFR1","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2025.101044_bib0083","doi-asserted-by":"crossref","first-page":"R369","DOI":"10.1530\/ERC-19-0087","article-title":"The NF-KB pathway and endocrine therapy resistance in breast cancer","volume":"26","author":"Khongthong","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0084","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1158\/1078-0432.CCR-17-2776","article-title":"Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer","volume":"24","author":"Mishra","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"Suppl 2","key":"10.1016\/j.ctarc.2025.101044_bib0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000444451","article-title":"Overcoming resistance to endocrine therapy in breast cancer: new approaches to a nagging problem","volume":"25","author":"Luqmani","year":"2016","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.ctarc.2025.101044_bib0086","doi-asserted-by":"crossref","DOI":"10.3390\/ph16091210","article-title":"CXCL8 Promotes endothelial-to-mesenchymal transition of endothelial cells and protects cells from erastin-induced ferroptosis via CXCR2-mediated activation of the NF-\u03bab signaling pathway","volume":"16","author":"Ji","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ctarc.2025.101044_bib0087","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1007\/s11033-021-06648-8","article-title":"An updated review on the role of the CXCL8-CXCR1\/2 axis in the progression and metastasis of breast cancer","volume":"48","author":"Mishra","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ctarc.2025.101044_bib0088","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3892\/or.2016.4557","article-title":"MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells","volume":"35","author":"Kim","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2025.101044_bib0089","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/jcm12062412","article-title":"Vascular endothelial growth factor ligands and receptors in breast cancer","volume":"12","author":"Brogowska","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2025.101044_bib0090","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/cncr.11764","article-title":"Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma","volume":"98","author":"Manders","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0091","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.e11564","article-title":"Vascular endothelial growth factor (VEGF)\u2013targeting therapies for endocrine-refractory or -resistant metastatic breast cancer (MBC): preliminary results of a systematic review and meta-analysis","volume":"29","author":"Wagner","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0092","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clbc.2011.03.010","article-title":"Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"11","author":"Yardley","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ctarc.2025.101044_bib0093","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.1074","article-title":"A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients","volume":"26","author":"Falkson","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0094","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2265055","article-title":"Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"24","author":"Tan","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ctarc.2025.101044_bib0095","article-title":"Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer","volume":"2012","author":"Wagner","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ctarc.2025.101044_bib0096","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1021\/pr2004117","article-title":"Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance","volume":"10","author":"Hengel","year":"2011","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0097","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fonc.2015.00140","article-title":"Unfolding the role of stress response signaling in endocrine resistant breast cancers","volume":"5","author":"Clarke","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0098","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-2935","article-title":"Abstract 2935: systematic drug testing and RNA-sequencing of tamoxifen resistant breast cancer cell lines","volume":"76","author":"Hultsch","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101044_bib0099","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273513","article-title":"Tamoxifen-resistant breast cancer cells exhibit reactivity with Wisteria floribunda agglutinin","volume":"17","author":"Hlaing","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2025.101044_bib0100","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/j.bmcl.2010.02.024","article-title":"Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder","volume":"20","author":"Ali","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ctarc.2025.101044_bib0101","doi-asserted-by":"crossref","first-page":"lqae019","DOI":"10.1093\/nargab\/lqae019","article-title":"Unraveling the complex relationship between mRNA and protein abundances: a machine learning-based approach for imputing protein levels from RNA-seq data","volume":"6","author":"Prabahar","year":"2024","journal-title":"NAR Genom. Bioinform."},{"key":"10.1016\/j.ctarc.2025.101044_bib0102","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101323","article-title":"Translational offsetting as a mode of estrogen receptor \u03b1-dependent regulation of gene expression","volume":"38","author":"Lorent","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.ctarc.2025.101044_bib0103","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1535-2","article-title":"In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition","volume":"16","author":"Cava","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ctarc.2025.101044_bib0104","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s13402-018-0400-x","article-title":"In silico screening for ER\u03b1 down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ER\u03b1-expressing breast cancer cells","volume":"41","author":"Busonero","year":"2018","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ctarc.2025.101044_bib0105","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1021\/acs.analchem.4c05138","article-title":"High-throughput empirical and virtual screening to discover novel inhibitors of polyploid giant cancer cells in breast cancer","volume":"97","author":"Ma","year":"2025","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ctarc.2025.101044_bib0106","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20240444","article-title":"Tamoxifen metabolites treatment promotes ER\u03b1+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance","author":"Mu\u00f1oz-Ayala","year":"2024","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ctarc.2025.101044_bib0107","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.breast.2014.02.008","article-title":"Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype","volume":"23","author":"Martinez de Due\u00f1as","year":"2014","journal-title":"Breast"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:45:38Z","timestamp":1766173538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":107,"alternative-id":["S2468294225001807"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101044","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101044"}}